ReviewCurrent opinion in virology2020
Dengue vaccine development by the year 2020: challenges and prospects.
Review in Current opinion in virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mathematical models for dengue fever epidemiology: A 10-year systematic review.Physics of life reviews · 2022Pooled it
- Efficacy of Probiotics and Postbiotics in Treating Dengue Fever - A Potential Strategy to Reduce Antibody-dependent Enhancement.Probiotics and antimicrobial proteins · 2026Review
- Characteristics, Motivation, and Challenges of Global Research on Dengue Vaccination.Reviews in medical virology · 2026Review
- "Addressing rising dengue burden in Pakistan: is it time to consider dengue vaccination?"Annals of medicine and surgery (2012) · 2026Article
- Peptide MegaPools Approach to Evaluate the Dengue-Specific CD4 and CD8 T-Cell Response.Pathogens (Basel, Switzerland) · 2025Article
- Interplay between innate immune cells and inflammatory mediators in dengue infection: an evolving therapeutic paradigm.Expert reviews in molecular medicine · 2025Review
- Discovery of Pyrazole-3-Carboxylic Acid Derivatives as Dengue Virus Protease Inhibitors with Antiviral Activity.ACS medicinal chemistry letters · 2025Article
- Reverse genetics rescue of sylvatic dengue viruses.Journal of virology · 2025Article
- Knowledge, attitude, and practice regarding dengue vaccine: a baseline study of community members and health providers in Indonesia.Clinical and experimental pediatrics · 2025Article
- Article
- Effective inhibition of dengue virus replication using 3'UTR-targeted Vivo-Morpholinos.Frontiers in immunology · 2024Article
- Emerging and re-emerging pediatric viral diseases: a continuing global challenge.Pediatric research · 2024Review
- Design, Synthesis, Evaluation and Molecular Dynamics Simulation of Dengue Virus NS5-RdRp Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2023Article
- China's public health initiatives for climate change adaptation.The Lancet regional health. Western Pacific · 2023Review
- Neutralizing antibodies from prior exposure to dengue virus negatively correlate with viremia on re-infection.Communications medicine · 2023Article
- A Prototype-Pathogen Approach for the Development of Flavivirus Countermeasures.The Journal of infectious diseases · 2023Review
- Frequent outbreaks of dengue fever in South Asian countries-A correspondence analyzing causative factors and ways to avert.Health science reports · 2023Article
- Effects of the source of information and knowledge of dengue fever on the mosquito control behavior of residents of border areas of Yunnan, China.Parasites & vectors · 2023Article
- Tracing down the Updates on Dengue Virus-Molecular Biology, Antivirals, and Vaccine Strategies.Vaccines · 2023Review
- Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine.BMC infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first licensed dengue vaccine led to considerable controversy, and to date, no dengue vaccine is in widespread use. All three leading dengue vaccine candidates are live attenuated vaccines, with the main difference between them being the type of backbone and the extent of chimerization. While CYD-TDV (the first licensed dengue vaccine) does not include non-structural proteins of dengue, TAK-003 contains the dengue virus serotype 2 backbone, and the Butantan/Merck vaccine contains three full-genomes of the four dengue virus serotypes. While dengue-primed individuals can already benefit from vaccination against all four serotypes with the first licensed dengue vaccine CYD-TDV, the need for dengue-naive population has not yet been met. To improve tetravalent protection, sequential vaccination should be considered in addition to a heterologous prime-boost approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.